18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma
about
18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma
description
clinical trial
@en
klinisch onderzoek
@nl
name
18F-FDG PET and Osimertinib in ...... tivated Recurrent Glioblastoma
@en
type
label
18F-FDG PET and Osimertinib in ...... tivated Recurrent Glioblastoma
@en
prefLabel
18F-FDG PET and Osimertinib in ...... tivated Recurrent Glioblastoma
@en
P1476
Creating Metabolic Vulnerabili ...... hibiting EGFR With Osimertinib
@en
P3098
NCT03732352
P4844
P580
2018-11-28T00:00:00Z
P582
2020-11-01T00:00:00Z